Collegium Pharmaceutical Inc (COLL)vsViatris Inc (VTRS)
COLL
Collegium Pharmaceutical Inc
$33.45
+2.11%
HEALTHCARE · Cap: $1.12B
VTRS
Viatris Inc
$15.38
-0.13%
HEALTHCARE · Cap: $19.19B
Smart Verdict
WallStSmart Research — data-driven comparison
Viatris Inc generates 1729% more annual revenue ($14.56B vs $796.33M). COLL leads profitability with a 9.4% profit margin vs -2.0%. VTRS earns a higher WallStSmart Score of 50/100 (C-).
COLL
Buy50
out of 100
Grade: C-
VTRS
Buy50
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+88.3%
Fair Value
$385.32
Current Price
$33.45
$351.87 discount
Intrinsic value data unavailable for VTRS.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 27 in profit
Attractively priced relative to earnings
Growing faster than its price suggests
Reasonable price relative to book value
Areas to Watch
Smaller company, higher risk/reward
Earnings declined 46.6%
Distress zone — elevated risk
Elevated debt levels
ROE of -2.0% — below average capital efficiency
Earnings declined 70.6%
Distress zone — elevated risk
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : COLL
The strongest argument for COLL centers on Return on Equity, P/E Ratio.
Bull Case : VTRS
The strongest argument for VTRS centers on PEG Ratio, Price/Book. PEG of 0.14 suggests the stock is reasonably priced for its growth.
Bear Case : COLL
The primary concerns for COLL are Market Cap, EPS Growth, Altman Z-Score. Debt-to-equity of 2.59 is elevated, increasing financial risk.
Bear Case : VTRS
The primary concerns for VTRS are Return on Equity, EPS Growth, Altman Z-Score.
Key Dynamics to Monitor
COLL profiles as a value stock while VTRS is a turnaround play — different risk/reward profiles.
VTRS carries more volatility with a beta of 0.90 — expect wider price swings.
COLL is growing revenue faster at 8.9% — sustainability is the question.
VTRS generates stronger free cash flow (348M), providing more financial flexibility.
Bottom Line
COLL scores higher overall (50/100 vs 50/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Collegium Pharmaceutical Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and markets pain management medications. The company is headquartered in Stoughton, Massachusetts.
Viatris Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?